Ovid Therapeutics Inc. — Net Income by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/92199aff-b47a-4aa8-97a8-ba91350c58fc/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-17.4M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-027621 |
| FY 2024 | $-26.4M | 2024-01-01 – 2024-12-31 | evidence 0001628280-26-027621 |
| FY 2023 | $-52.3M | 2023-01-01 – 2023-12-31 | evidence 0001628280-26-027621 |
| FY 2022 | $-54.2M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-007648 |
| FY 2021 | $122.8M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-003668 |
| FY 2020 | $-81.0M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-013016 |
| FY 2019 | $-60.5M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-010108 |
| FY 2018 | $-52.0M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-006804 |
| FY 2017 | $-64.8M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-007152 |
| FY 2016 | $-22.4M | 2016-01-01 – 2016-12-31 | evidence 0001564590-18-007152 |
| FY 2015 | $-13.2M | 2015-01-01 – 2015-12-31 | evidence 0001564590-18-007152 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Ovid Therapeutics Inc. — all facts · Revenue · Operating Income